Skip to content

Study · Randomized controlled trial · 2015

9 results

Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.

Malm-Erjefält M, Ekblom M, Vouis J, Zdravkovic M, Lennernäs H

Molecular pharmaceutics12 Oct 2015Cited by 25 (Europe PMC)

PMID26426736 (opens in a new tab)DOI10.1021/acs.molpharmaceut.5b00278 (opens in a new tab)PepBankPUB-26426736
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, atorvastatin tmax was delayed by up to 2 h compared with placebo.

    In plain wordsIn healthy adults taking liraglutide, the cholesterol drug atorvastatin reached its peak blood level later than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseAtorvastatin tmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h)
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, lisinopril tmax was delayed by up to 2 h compared with placebo.

    In plain wordsIn healthy adults taking liraglutide, the blood pressure drug lisinopril reached its peak blood level later than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseLisinopril tmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h)
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, digoxin tmax was delayed by up to 2 h compared with placebo.

    In plain wordsIn healthy adults taking liraglutide, the heart drug digoxin reached its peak blood level later than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseDigoxin tmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h)
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  4. 04HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, atorvastatin Cmax was reduced by 27-38% (range across three drugs) and did not meet the bioequivalence criterion.

    In plain wordsIn healthy adults taking liraglutide, the peak blood level of atorvastatin was lower than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseAtorvastatin Cmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    Cmax reduction (range across atorvastatin, lisinopril, digoxin)
    27 to 38%
    atorvastatin

    Source sentences

    Summary
    With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h) and did not meet the criterion for bioequivalence for Cmax (reduced Cmax by 27-38%)
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  5. 05HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, lisinopril Cmax was reduced by 27-38% (range across three drugs) and did not meet the bioequivalence criterion.

    In plain wordsIn healthy adults taking liraglutide, the peak blood level of lisinopril was lower than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLisinopril Cmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    Cmax reduction (range across atorvastatin, lisinopril, digoxin)
    27 to 38%
    lisinopril

    Source sentences

    Summary
    With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h) and did not meet the criterion for bioequivalence for Cmax (reduced Cmax by 27-38%)
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  6. 06HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, digoxin Cmax was reduced by 27-38% (range across three drugs) and did not meet the bioequivalence criterion.

    In plain wordsIn healthy adults taking liraglutide, the peak blood level of digoxin was lower than with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseDigoxin Cmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    Cmax reduction (range across atorvastatin, lisinopril, digoxin)
    27 to 38%
    digoxin

    Source sentences

    Summary
    With liraglutide, the oral drugs atorvastatin, lisinopril, and digoxin showed delayed tmax (by ≤2 h) and did not meet the criterion for bioequivalence for Cmax (reduced Cmax by 27-38%)
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  7. 07HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, griseofulvin tmax was similar to placebo.

    In plain wordsIn healthy adults taking liraglutide, the antifungal drug griseofulvin reached its peak blood level at a similar time as with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGriseofulvin tmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    griseofulvin had similar tmax and 37% increased Cmax.
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  8. 08HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, griseofulvin Cmax was 37% higher than with placebo.

    In plain wordsIn healthy adults taking liraglutide, the peak blood level of griseofulvin was higher than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseGriseofulvin Cmax with liraglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Measurements

    Cmax increase
    37%
    griseofulvin

    Source sentences

    Summary
    griseofulvin had similar tmax and 37% increased Cmax.
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…
  9. 09HumanRandomized controlled trialPharmacokinetics

    In healthy subjects at steady state of liraglutide 1.8 mg, the overall plasma exposure (AUC) of the four oral drugs showed only minor changes that were not considered clinically relevant.

    In plain wordsIn healthy adults taking liraglutide, the total blood exposure to four other oral drugs changed only slightly, not enough to matter clinically.

    Peptide
    Liraglutide
    Outcome
    No significant changeOverall exposure (AUC) of griseofulvin, atorvastatin, lisinopril and digoxin
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    1.8 mgAs given in this study (human).

    Source sentences

    Summary
    the overall plasma exposure (AUC) of griseofulvin, atorvastatin, lisinopril, and digoxin only exhibited minor changes and was not considered to be of clinical relevance.
    1 context sentence
    Summary · context
    single-dose pharmacokinetics of drugs representing BCS classes II (low solubility-high permeability; atorvastatin 40 mg and griseofulvin 500 mg), III (high solubility-low permeability; lisinopril 20 mg), and IV (low solubility-low permeability; digoxin 1 mg) were studied in healthy subjects at stead…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01518166

Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH

Novo Nordisk A/Sn = 70May 2006 to Apr 2007

Diabetes · Healthy

Trial pageClinicalTrials.govUpdated 25 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.